A filing with the U.S. Securities and Exchange Commission shows an insider identified as Daljit Singh Aurora disposed of large blocks of stock in Neumora Therapeutics Inc. (NASDAQ: NMRA) across several days in August. The disclosures, made public on Aug. 21, list multiple transactions that reduced the named insider’s stake by roughly 30.16 per cent.
Details of the disclosed transactions
The filing records a series of sales between Aug. 17 and Aug. 21. The most recent disclosed transaction on Friday, Aug. 21, shows the sale of 21,055 shares at an average price of US$1.60 per share for a total of US$33,688.00. After that sale the filing states the insider held 48,750 shares of the company, with an approximate value of US$78,000 based on the reported prices.
Other sizeable disposals disclosed in the same filing include:
- Aug. 20 — sale of 66,711 shares at about US$1.51 per share for US$100,733.61.
- Aug. 20 — sale of 67,741 shares at about US$1.51 per share for US$102,288.91.
- Aug. 21 — sale of 20,553 shares at about US$1.59 per share for US$32,679.27.
- Aug. 19 — sale of 30,918 shares at about US$1.65 per share for US$51,014.70.
- Aug. 19 — sale of 31,000 shares at about US$1.65 per share for US$51,150.00.
- Aug. 17 — sale of 55,016 shares at about US$1.50 per share for US$82,524.00.
- Aug. 17 — sale of 91,690 shares at about US$1.50 per share for US$137,535.00.
- Aug. 18 — sale of 34,987 shares at about US$1.59 per share for US$55,629.33.
- Aug. 18 — sale of 34,162 shares at about US$1.59 per share.
| Date | Shares sold | Avg. price (US$) | Reported value (US$) |
|---|---|---|---|
| Aug. 21 | 21,055 | 1.60 | 33,688.00 |
| Aug. 20 | 66,711 | 1.51 | 100,733.61 |
| Aug. 20 | 67,741 | 1.51 | 102,288.91 |
| Aug. 21 | 20,553 | 1.59 | 32,679.27 |
What the filings mean — and what they don’t
Insider filings with the SEC are designed to provide transparency when corporate insiders buy or sell company stock. For local investors in Ontario and across Canada, such disclosures can be one piece of information when assessing a company. However, filings alone do not explain the insider’s motivations.
"The sale was disclosed in a document filed with the Securities & Exchange Commission," the filing states.
Insiders sell shares for many reasons: portfolio rebalancing, tax planning, exercising option-related obligations, diversification, or personal liquidity needs. An insider sale does not automatically mean the company’s prospects have deteriorated. Conversely, persistent or large-scale selling by an insider can merit closer scrutiny by shareholders and analysts.
Neumora Therapeutics is a U.S.-listed clinical-stage neuroscience company. The SEC filing summarises the transactions and the resulting reduction in the insider’s holding to about 48,750 shares, representing a decline of approximately 30.16 per cent from the position prior to the sales.
Local implications and investor guidance
For Aurora-area residents who hold or watch biotech stocks, the filing is a reminder to consult multiple sources before changing investment positions. Consider company filings, recent clinical or regulatory announcements, analyst commentary and broader market conditions. If in doubt, speak with a registered financial adviser who can situate insider activity within an investor’s overall plan.
The SEC document cited in the disclosure is publicly available and provides the formal record of the transactions. Local investors who follow U.S.-listed biotechs should regularly check regulatory filings for developments that could affect their portfolios.
WE NEWS will continue to monitor corporate disclosures and provide updates of material developments that affect investors in Aurora and beyond.
